Literature DB >> 28652432

Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.

Evangelos Tsiambas1,2, Nicholas S Mastronikolis3, Alicia Y Lefas4, Stavros N Georgiannos5, Vasileios Ragos6, Panagiotis P Fotiades7, Nikolaos Tsoukalas8, Nikolaos Kavantzas2, Andreas Karameris9, Dimitrios Peschos10, Efstratios Patsouris2, Konstantinos Syrigos11.   

Abstract

BACKGROUND/AIM: Epidermal growth factor receptor (EGFR) over-activation is observed in significant proportions of non-small cell lung carcinomas (NSCLC). Our aim was to investigate the role of chromosome 7 multiplication with regard to its influence in EGFR expression, combined or not with gene amplification.
MATERIALS AND METHODS: Using tissue microarray technology, fifty (n=50) primary NSCLCs were cored and re-embedded into the final recipient block. Immunohistochemistry (IHC) and also chromogenic in situ hybridization (CISH) were performed.
RESULTS: EGFR expression at any level was detected in 40/50 (80%) cores. Over-expression was observed in 23/40 (57.5%) cases. Gene amplification was identified in 11/50 (22%) cases whereas chromosome 7 polysomy in 8/50 (16%) cases. Pure chromosome 7 multiplication alone led to low or moderate levels of expression. Overall EGFR expression was correlated with gene (p=0.001) and interestingly with chromosome 7 centromere numerical imbalances (p=0.004).
CONCLUSION: EGFR expression is associated not only with amplification, but also with chromosome 7 centromere multiple copies. Chromosome 7 multiplication -due to centromere region amplification or true polysomy- is critical for applying monoclonal antibody targeted therapeutic strategies excluding the pure non-amplified cases. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lung; carcinoma; chromosome; epidermal growth factor receptor; gene; tissue microarray

Mesh:

Substances:

Year:  2017        PMID: 28652432      PMCID: PMC5566915          DOI: 10.21873/invivo.11106

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  43 in total

1.  Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression.

Authors:  H Buerger; F Gebhardt; H Schmidt; A Beckmann; K Hutmacher; R Simon; R Lelle; W Boecker; B Brandt
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

2.  Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event.

Authors:  I-Tien Yeh; Mathew A Martin; Ryan S Robetorye; Aswani R Bolla; Chris McCaskill; Rashmi K Shah; Mercedes E Gorre; Mansoor S Mohammed; Shelly R Gunn
Journal:  Mod Pathol       Date:  2009-05-15       Impact factor: 7.842

3.  Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.

Authors:  Giuseppe Viale
Journal:  J Pathol       Date:  2009-09       Impact factor: 7.996

4.  A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

Authors:  Wanqing Liu; Federico Innocenti; Michael H Wu; Apurva A Desai; M Eileen Dolan; Edwin H Cook; Mark J Ratain
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

5.  Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

Authors:  Sanja Dacic; Melina Flanagan; Kathleen Cieply; Suresh Ramalingam; James Luketich; Chandra Belani; Samuel A Yousem
Journal:  Am J Clin Pathol       Date:  2006-06       Impact factor: 2.493

Review 6.  Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations.

Authors:  Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2014-08

7.  Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy.

Authors:  Laura C Matthews; Andrew A Berry; David J Morgan; Toryn M Poolman; Kerstin Bauer; Frederike Kramer; David G Spiller; Rachel V Richardson; Karen E Chapman; Stuart N Farrow; Michael R Norman; Andrew J K Williamson; Anthony D Whetton; Stephen S Taylor; Jan P Tuckermann; Michael R H White; David W Ray
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

Review 8.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

Authors:  Tianhong Li; Hsing-Jien Kung; Philip C Mack; David R Gandara
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

Review 9.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

10.  Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

Authors:  Daniel B Costa; Susan T Schumer; Daniel G Tenen; Susumu Kobayashi
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

View more
  2 in total

1.  CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.

Authors:  Li-Chi Huang; Ka-Wai Tam; Wei-Ni Liu; Chun-Yu Lin; Kai-Wen Hsu; Wen-Shyang Hsieh; Wei-Ming Chi; Ai-Wei Lee; Jinn-Moon Yang; Ching-Ling Lin; Chia-Hwa Lee
Journal:  Dis Markers       Date:  2018-04-12       Impact factor: 3.434

2.  Modulation of proliferation factors in lung adenocarcinoma with an analysis of the transcriptional consequences of genomic EGFR activation.

Authors:  Melanie Haas Kucherlapati
Journal:  Oncotarget       Date:  2019-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.